EPO 018B

Drug Profile

EPO 018B

Alternative Names: EPO-018B; Pegol Sihematide; Peihuaxi hippocampal peptide

Latest Information Update: 28 Oct 2015

Price : $50

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Class Anti-inflammatories; Antianaemics; Peptides; Polyethylene glycols
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Anaemia

Most Recent Events

  • 01 Oct 2015 Phase-II clinical trials in Anaemia (In adults, In the elderly, Treatment-experienced) in China (IV) (NCT02586402)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top